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Extension of Grizzle’s Classic Crossover Design 
 
James F. Reed III 
Christiana Care Hospital System, 
Newark, Delaware 
 
 
The crossover design compares treatments A and B over two periods using sequences AB and BA (the 
AB|BA design) and is the classic design most often illustrated and critiqued in textbooks. Other crossover 
designs have been used but their use is relatively rare and not always well understood. This article 
introduces alternatives to a randomized two-treatment, two-period crossover study design. One strategy, 
which is to extend the classic AB|BA by adding a third period to repeat one of the two treatments, has 
several attractive advantages; an added treatment period may not imply a large additional cost but will 
allow carryover effects to be estimated and compared with the within-subject variability. Careful choice 
of treatment sequences will enable the first two trial periods to constitute a conventional two-period 
crossover trial if the third treatment period leads to excessive subject drop-outs. Four alternative designs 
that address the first-order carryover effect are presented. These designs have more statistical power than 
the classic design and allow the treatment effects to be estimated, even in the presence of a carryover 
effect. 
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Introduction 
A crossover study is a longitudinal study in 
which subjects receive a sequence of different 
treatments; these designs are common in many 
scientific disciplines. In AB|BA crossover 
studies, subjects are randomly assigned to 
receive either treatment A in the first treatment 
period followed by treatment B in the second 
period or treatment B in the first period followed 
by treatment A in the second period. The 
crossover study allows for a within-subject 
comparison between treatments because each 
subject serves as his or her own control, the 
inter-patient variability is removed from the 
comparison between treatments and it can 
provide unbiased estimates for the differences 
between treatments. However, frequent 
misapplications of the design in clinical trials 
and even more frequent misanalysis of the data  
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have nearly doomed the crossover trial in 
clinical research (Freeman, 1989; Senn, 1994; 
Senn, 1996). 
The most damning characteristic of a 
crossover study is the potential of a carryover 
effect of one treatment to the next period. To 
address this issue, researchers typically include 
washout periods in their study designs. These 
washout periods are thought to be of sufficient 
length to negate any lingering effect of one 
treatment into the next period. Unfortunately, 
what a sufficiently long washout period might be 
remains unclear. In this article, and in most of 
the literature on crossover designs, the 
persistence of a carryover effect is assumed to 
last for only a single period (a first-order 
carryover effect) and it is also assumed that the 
carryover effect is different for different 
treatments. If a carryover effect is suspected in 
any crossover trial, then a term for this effect 
must be included in the model and accounted for 
in the subsequent analysis. This article 
introduces three simple alternatives to Grizzle’s 
classic AB|BA crossover design. These designs 
have more statistical power than the AB|BA 
design and allow unbiased treatment effects to 
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be estimated, even when a simple-order 
carryover effect is specified. 
 
The Traditional Crossover Model with 
Continuous Data 
The traditional design model assumes 
that each treatment has a simple first-order 
carryover effect that does not interact with the 
direct effect of the treatment in the subsequent 
period and that subject effects are either fixed or 
random. Although a variety of models are 
considered in the literature, virtually all of the 
work in crossover designs has the following 
traditional statistical model which assumes the 
following for the response of patient yij. 
If yijk denotes the observed response of 
subject j (j = 1, …, n) in period i (i = 1, …, p), 
then 
 
yij = µ + πi + τd(i,j) + λd(i-1,j) + βj + εij. 
 
where πi is the effect of period i; τd(i,j) is the 
direct effect of treatment D, λd(i-1,j) is the simple 
first-order carryover effect of treatment D and 
d(i,j) is the treatment allocated to patient j in 
period i, λd(0,j) = 0 for all j. It is assumed that all 
these effects are fixed effects. βj is the effect of 
patient j and εij is the error term. The random 
subject effect, βj, and the experimental error, εij, 
are assumed to be mutually independently 
distributed as N (0, σ2β) and N(0, σ2ε). 
 
The Classic AB|BA 
The crossover design that compares 
treatments A and B over two periods using 
sequences AB and BA (the AB|BA design) is 
the classic design and is most often illustrated 
and critiqued in textbooks (Grizzle, 1965). Other 
crossover designs have been utilized but their 
use is relatively rare and is not always well 
understood. For example, when more than two 
treatments are to be compared, an extensive use 
of each subject may be desirable when the 
number of periods can be extended. 
The primary purpose of an AB|BA 
crossover trail is to estimate the treatment 
contrast τA- τB (see Table 1). The period effects 
π1 and π2, the first-order carryover effects λA and 
λB, and µ are typically regarded as nuisance 
parameters that should be eliminated from any 
estimate. In sequence AB, the contrast c1, y11 – 
y21, has the expected value of E[c1] = E[y11 – y21] 
= (π1 - π2) + (τA - τB) - λA, while in sequence 
BA, the contrast c2, y21 – y22, has the expected 
value of E[c2] = E [y21 – y22] = (π1 - π2) - (τA - 
τB) - λB.  
The difference between contrasts c1 and 
c2 may be expressed is 2(τA - τB) - (λA - λB). It is 
then possible to generate a hypothesis by 
forming the differences in the two contrasts 
between responses for the two periods. That 
difference for the respective patients may be 
expressed by HCROS:{2(τA - τB) - (λA - λB) = 0}. 
HCROS is a combined null hypothesis tested by 
the difference (or crossover) test of equality of 
both the treatment effects and carryover effects 
of A and B {τA = τB, λA = λB}. The treatment 
effect and carryover effect are said to be aliased. 
The rejection of HCROS is interpreted as 
demonstrating that the direct and/or carryover 
effects of A and B are different in the sense of a 
prevailing larger response for one treatment than 
the other across the two periods. 
In sequence AB, the contrast c3 ,y11 + 
y21, has the expected value of E[c3]= E[y11 + y21] 
= 2μ + (π1 + π2 ) + (τA + τB) + λA, and in 
sequence BA, the contrast c4 , y21 + y22, has the 
expected value of E[c4] = E[y21 + y22] = 2μ + (π1 
+ π2 ) + (τA + τB) + λB. The difference between 
c3 and c4 differ by λA - λB, and is a measure of 
the net carryover effect.  
The hypothesis, HSEQ: λA = λB, has been 
proposed for use when deciding whether the 
rejection of the hypothesis HCROS is due mainly 
to differences between the direct treatment 
effects τA = τB or between the carryover effects 
λA = λB. A non-significant HSEQ supports the 
contention that there is a difference between τA 
and τB as the primary contradiction of HCROS. 
Alternatively, a significant HSEQ is interpreted as 
indicating that the differences between λA and 
λB may account for the contradiction of HCROS. 
When assessing the SEQ hypothesis, the type II 
error (falsely failing to reject the null hypothesis 
of no first-order carryover effect) is of some 
concern.  
To reduce the probability of making a 
type II error, the recommendation has been to 
use larger than the usual α, such as 25%. In 
bioequivalence studies, the commonly used 
significance level in a bioequivalence study for  
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SEQ is 25% (Chen & Tsong, 2007). This 
recommendation may be followed for any 
analyses. 
A third hypothesis compares the two 
sequences with respect to the responses for the 
first period only. The prevailing strategy is to 
use this test if a significant carryover effect is 
identified. This test procedure is referred to as 
PAR. When data from the second period are 
ignored, an AB/BA crossover design has the 
same structure as a PARallel group trial. PAR 
addresses the hypothesis of equality of direct 
treatment effects of A and B in the presence of 
unequal carryover effects (Freeman, 1986; 
Willan & Pater, 1986). An unbiased estimator of 
the treatment effect can be found by means of a 
t-test applied to the measurements obtained in 
the first period only; however, unfortunately, 
when using data from the first period only, 
advantages of the crossover design are negated. 
 
Balaam’s Design 
To solve the first-order crossover 
problem inherent in the traditional AB|BA 
design, an extension of the Grizzle design is 
needed. One alternative involves the use of 
additional treatment sequences in the two 
periods. For example, AA|AB|BA|BB (Balaam, 
1968)   could   be   utilized.   This   design   is  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
universally optimal for estimating treatment 
effects regardless of whether baseline 
observations are available, and it is far more 
efficient than the classic AB|BA (Laska, 
Meisner & Kushner, 1983). However, in the 
absence of any carryover effect, this design is 
inefficient because many of the subjects will 
contribute little - if any - information to the 
estimate of treatment differences in the AA and 
BB sequences. 
The schematic for this design is shown 
in Table 2. In sequence AB, the contrast, c1 = 
(y11 - y12), has an expected value of E[c1] = E[y11 
– y12] = (π1 - π2) + (τA - τB) - λA, in sequence 
BA, the contrast c2 = (y21 - y22), has expected 
value of E[c2] = E[y21 – y22] = (π1 - π2) - (τA - τB) 
- λB, in sequence AA, the contrast c3 has an 
expected value of E[c3] = E[y31 – y32] = (π1 - π2) 
- λA, and in sequence BB, the contrast c4 has an 
expected value of E[c4] = E[y41 – y42] = (π1 - π2) 
- λB. A linear combination of c1 - c2 - c3 + c4 
yields an unbiased estimate of the treatment 
differences. 
To derive an unbiased estimate of 
carryover effects, c5 is defined in sequence AB 
as y11 + y21. The expected value of c5 is then 
E[c5] = E[y11 + y21] = 2µ + (π1 + π2) + (τA + τB) 
+ λA. In sequence BA, c6 is defined as y21 + y22  
Table 1: Design AB|BA 
 
AB|BA Design Period 1 (k = 1) 
Period 2 
(k = 2) 
Sequence AB (i = 1) μ + π1 + τA µ + π2 + τB + λA 
Sequence BA (i = 2) µ + π1 + τB µ + π2 + τA + λB 
Table 1 Notes: 
Sequence AB (i = 1): E(yAB,1) = μAB,1 = μ + π1 + τA, E(yAB,2) = μAB,2 = μ + π2 + τB + λA 
Sequence BA (i = 2): E(yBA,1) = μBA,1 = μ + π1 + τB, E(yAB,2) = μBA,2 = μ + π2 + τA + λB 
In sequence AB, the contrast c1 has the expected value of E[c1]=E[y11 – y21]=(π1 - π2) + (τA - τB) - λA 
In sequence BA, the contrast c2 has the expected value of E[c2]=E[y21 – y22]=(π1 - π2) - (τA - τB) - λB 
In sequence AB, the contrast c3 has the expected value of E[c3]=E[y11 + y21] = 
2μ+(π1+π2)+(τA+τB)+λA 
In sequence BA, the contrast c4 has the expected value of E[c4]=E[y21 + y22] = 
2μ+(π1+π2)+(τA+τB)+λB 
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and has the expected value of E[c6] = E[y21 + 
y22] = 2µ + (π1 + π2) + (τA + τB) + λB. A linear 
combination of [½(c5 - c6 - c3 + c4)] yields an 
unbiased estimate of carryover effects (λA - λB). 
 
Two-Treatment, Three-Period Crossover Design 
The second design strategy is to extend 
the AB|BA design by adding a third period and 
repeating one of the two treatments: This has 
several attractive advantages. For example, in 
clinical studies major costs are associated with 
planning and patient recruitment rather than 
routine follow-up, thus, an added period may not 
imply a large additional cost. The added 
treatment period will allow carryover effects to 
be estimated and compared with the within-
subject variability. Finally, a careful selection of 
the treatment sequences to be used will insure 
that the first two trial periods constitute a 
conventional two-period crossover trial if the 
third treatment period leads to excessive subject 
drop-outs. 
In three period crossover trial with two 
treatments, six possible treatment sequences can 
result when two treatments are applied in three 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
periods. Two of these sequences, AAB and BBA 
can be omitted because they do not enable 
carryover effects from A and B to be examined 
in the same subject and the first two periods do 
not constitute a conventional two-period 
crossover design.  
The four remaining sequences ABB, 
BAA, ABA and BAB may be used in pairs to 
form two-treatment sequence three-period 
designs, three-treatment sequence three-period 
designs and one four-treatment sequence three-
period design. Of the two-treatment sequence, 
three-period, the ABB|BAA is known to be the 
universally optimal design within the class of 
three periods (Cheng & Wu, 1980; Laska & 
Meisner, 1985; Hedayat & Stufken, 2003). In 
these designs half the subjects are randomly 
assigned to each sequence. 
Two additional efficient two-treatment, 
three-period designs are the AAB|ABA and 
ABA|ABB designs. Another efficient two-
treatment, three-period design is the ABB| 
BAA|ABA|BAB (Ebbutt, 1984). This set of 
designs with equal number of subjects per 
sequence is able to estimate all parameters in the 
Table 2: Balaam’s Design (AB|BA|AA|BB) 
 
AB|BA Design Period 1 (k = 1) 
Period 2 
(k = 2) 
Sequence AB (i = 1) μ + π1 + τA µ + π2 + τB + λA 
Sequence BA (i = 2) µ + π1 + τB µ + π2 + τA + λB 
Sequence AA (i = 3) μ + π1 + τA µ + π2 + τA + λA 
Sequence BB (i = 4) μ + π1 + τB µ + π2 + τB + λB 
 
Table 2 Notes: 
Sequence AB (i = 1): E(yAB,1) = μAB,1 = μ + π1 + τA, E(yAB,2) = μAB,2 = μ + π2 + τB + λA 
Sequence BA (i = 2): E(yBA,1) = μBA,1 = μ + π1 + τB, E(yAB,2) = μBA,2 = μ + π2 + τA + λB 
Sequence AA (i = 3): E(yBA,1) = μAA,1 = μ + π1 + τA, E(yAB,2) = μBA,2 = μ + π2 + τA + λA 
Sequence BB (i = 4): E (yBA,1) = μBA,1 = μ + π1 + τB, E (yAB,2) = μBA,2 = μ + π2 + τB + λB 
In sequence AB, the contrast c1 has the expected value of E[c1] = E[y11 – y21]=(π1 - π2) + (τA - τB) - λA 
In sequence BA, the contrast c2 has the expected value of E[c2] = E[y21 – y22]=(π1 - π2) - (τA - τB) - λB 
In sequence AA, the contrast c3 has the expected value of E[c3] = E[y31 – y32]=(π1 - π2) - λA 
In sequence BB, the contrast c4 has the expected value of E[c4] = E[y41 – y42]=(π1 - π2) - λB 
In sequence AB, the contrast c5 has the expected value of E[c5] = E[y11 + y21]=2µ+(π1 + π2)+(τA + τB)+λA 
In sequence BA, the contrast c6 has the expected value of E[c6] = E[y21 + y22]=2µ+(π1 + π2)+(τA + τB)+λB 
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traditional model and provide a good estimate of 
the treatment contrast (Ebbutt, 1984; Heydat & 
Stufken, 2003, Liang & Carriere, 2010). 
A balanced model for the two-treatment 
three-period crossover trial, ABB| BAA, is 
shown in Table 3. In sequence ABB, the 
contrast, c1 = (2y11 - y21 - y31), has the 
expectation ¼{(2π1 - π2 - π3) + 2(τA - τB) - λA - 
λB}. In sequence BAA, the contrast c2 = (2y21 - 
y22 – y32) has the expectation ¼{(2π1 - π2 - π3) + 
2(τB - τA) - λA - λB}. The difference between 
contrast c1 and c2 forms an unbiased estimator of 
τA - τB. It appears that the central problem of the 
AB|BA has been solved by simply extending the 
design by one period. An unbiased estimator of 
any carryover effect, λA - λB may also be 
constructed. Consider c3 = (y11 - 2y21 + y31) and 
c4 = (y21 - 2y22 + y23). The expected value of E 
[c3] is ⅓ {(π1 - 2π2 + π3) + (τA - τB) - 2λA + λB} 
and the expected value of E [c4] is ⅓ {(π1 - 2π2 + 
π3) + (τB - τA) - 2λB + λA}. The difference  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
between c3 and c4 forms an unbiased estimate of 
λA - λB. 
A second model for a two-treatment 
three-period crossover trial, ABA| BAB, is 
shown in Table 4. In sequence ABA, the 
expected value of E [c1] = E [½ (2y11 - y21 - y31)] 
= ½{(2π1 - π2 - π3) + (τA - τB) - λA - λB}. In 
sequence BAB, the expected value of E [c2] = E 
[½ (2y12 - y22 - y32)] = ½{(2π1 - π2 - π3) - (τA - 
τB) - λA - λB}. The difference between the means 
of the two contrasts c1 and c2 forms an unbiased 
estimator of τA - τB. In testing for carryover 
effect, let c3 = y11 + 2y21 + y31 in sequence ABA 
and the expected value of E [c3] = E [(y11 + 2y21 
+ y31)] = {4µ + (π1 + 2π2 + π3) + 2(τA + τB) + 
2λA + λB}. In sequence BAB, define c4 = y21 + 
2y22 + y23 with the expected value of E [c4] = E 
[(y21 + y22 - 2y23)] = {4µ + (π1 + 2π2 + π3) + 2(τA 
+ τB) + 2λB + λA}. The difference between c3 
and c4 then forms an unbiased estimate of λA - 
λB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: ABB|BAA Design 
 
Sequence Period 1 (k = 1) 
Period 2 
(k = 2) 
Period 3 
(k = 3) 
ABB (i = 1) µ + π1 + τA µ + π2 + τB + λA µ + π3 + τB + λB 
BAA (i = 2) µ + π1 + τB µ + π2 + τA + λB µ + π3 + τA + λA 
 
Table 3 Notes: 
ABB (i = 1): E(yABB,1) = μ + π1 + τA, E(yABB,2) = μ + π2 + τB + λA, E(yABB,3) = μ + π3 + τB + λB 
BAA (i = 2): E(yBAA,1) = μ + π1 + τB, E(yBAA,2) = μ + π2 + τA + λB, E(yBAA,3) = μ + π3 + τA + λA 
In sequence ABB, the expected value of E[c1]=E[¼(2y11 - y21 - y31)]=¼{(2π1 - π2 - π3)+2(τA - τB) - λA - 
λB} 
In sequence BAA, the expected value of E[c2]=E[¼ (2y21 - y22 - y32)]=¼{(2π1 - π2 - π3) + 2(τB - τA) - λA 
- λB} 
In sequence ABB, the expected value of E[c3]=E[⅓ (y11 - 2y21 + y31)]=⅓{(π1 - 2π2 + π3) + (τA - τB) - 2λA 
+ λB} 
In sequence BAA, the expected value of E[c4]=E[⅓ (y21 - 2y22 + y23)]=⅓{(π1 - 2π2 + π3) + (τB - τA) - 2λB 
+ λA} 
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Discussion 
Advantages of a crossover trial are that each 
subject is used as their own control, optimal two 
treatment three-period crossover designs are 
statistically efficient and these designs require 
fewer subjects for the same number of 
observations than do non-crossover designs. 
This latter advantage is an important aspect, 
particularly in situations where the experimental 
subjects are scarce and are expensive to recruit 
and maintain in the study. Another advantage of 
crossover designs is that, by a defining a specific 
choice of treatment sequences, it is possible to 
estimate important treatment contrasts even 
when assuming a carryover effect in the overall 
model. 
The major concern in a crossover design 
is the presence of carryover effects. In any given 
period, an observation from a subject is affected 
not only by the direct effect of a treatment in the 
period in which it is applied, but possibly by the 
effect of a treatment applied in the preceding 
period. In a clinical study, particularly a drug 
study, one way to avoid the impact of a 
carryover effect is to insert a rest period between 
two successive periods with the hope that the 
carryover effect would wash out during this 
period. This is the most common method of 
handling effects of drug studies. The insertion of 
rest periods effectively increases the interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
between the observed periods and may help in 
overcoming the carryover effect if the carryover 
effect is not expected to persist, however, 
inserting rest periods may not be feasible. The 
insertion of a rest period between each pair of 
successive periods increases the total duration of 
the experiment and there is no guarantee that the 
wash out period is sufficiently long enough to 
eliminate any carryover effect. An alternative is 
to design the experiment in such a manner that 
the difference in treatment effects may be 
estimated after adjusting for the presence of 
possible carryover effects. 
Despite some of the problems associated 
with the use of a crossover design its advantages 
are attractive. Although crossover designs have 
been in use for several decades, issues relating to 
the finding optimal crossover designs have been 
addressed only in about the last 30 years. There 
has been a continuous effort in the general area 
of optimal crossover designs, often assuming 
different underlying models. The uniform 
consistency has been the inclusion of carryover 
effect. These models, in turn, may be regarded 
as an approximation to the real world 
relationship between the response and the effects 
included in the model. A caution worth noting: 
Any crossover design under an assumed model 
might not be the optimal if the model is 
incorrectly specified. 
Table 4: ABA|BAB 
 
Sequence Period 1 (k = 1) 
Period 2 
(k = 2) 
Period 3 
(k = 3) 
ABA (i = 1) µ + π1 + τA µ + π2 + τB + λA µ + π3 + τA + λB 
BAB (i = 2) µ + π1 + τB µ + π2 + τA + λB µ + π3 + τB + λA 
 
Table 4 Notes: 
ABA (i = 1): E(yABB,1) = μ + π1 + τA, E(yABA,2) = μ + π2 + τB + λA, E(yABA,3) = μ + π3 + τA + λB 
BAB (i = 2): E(yBAB,1) = μ + π1 + τB, E(yBAB,2) = μ + π2 + π3 + λB, E(yBAB,3) = μ + π3 + τB + λA 
In sequence ABA, E[c1] = E[½ (2y11 - y21 - y31)] = ½{(2π1 - π2 - π3) + (τA - τB) - λA - λB } 
In sequence BAB, E[c2] = E[½ (2y21 - y22 - y32)] = ½{(2π1 - π2 - π3) - (τA - τB) - λA - λB} 
In sequence ABA, E[c3] = E[(y11 + 2y21 + y31)] = {4µ + (π1 + 2π2 + π3) + 2(τA + τB) + 2λA + λB} 
In sequence BAB, E[c4] = E[(y21 + 2y22 + y32)] = {4µ + (π1 + 2π2 + π3) + 2(τA + τB) + 2λB + λA} 
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Conclusion 
Although there are crossover models that specify 
higher order carryover effects, the two-treatment 
three-period designs described herein maintain 
their optimality characteristics. To address the 
potential of first-order carryover effect, the 
classic AB|BA crossover design could be 
extended to a three-period design using one of 
the designs outlined. In effect, the added 
treatment period permits any carryover effects to 
be estimated and compared with the within-
subject variability. A careful selection of the 
treatment sequences would reduce to a classic 
two-treatment, two-period conventional 
crossover trial if the third treatment period leads 
to excessive subject drop-outs. 
The statistical properties of two-
treatment, three-period designs is well known 
but seldom used. When the traditional statistical 
model is acknowledged as being reasonable, 
these designs provide a framework to estimate 
treatment effects even in the presence of a 
carryover effect and effectively provide a way to 
address the impasse imposed by the classic 
AB|BA design. 
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